Autoimmune Hepatitis (AIH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Autoimmune hepatitis (AIH) is a non-contagious, chronic, inflammatory, autoimmune disease in which one’s own immune system attacks healthy, normal liver cells.

Etiology-
The exact cause of autoimmune hepatitis is unknown. It is believed to be due to a combination of environmental, genetic, and immunologic factors.

Classification-
There are two clinically relevant types of AIH, including type 1and type 2.
Type 1- also referred to as the classic type, is typically diagnosed in adulthood
Type 2 autoimmune hepatitis is less common and generally affects girls between the ages of 2 and 14.

Epidemiology- The new cases per year (incidence) are estimated at 1-2 per 100,000 and total cases (prevalence) are approximately 24 per 100,000.

Geography Covered:-
North America- United States and Canada
Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Other countries- Japan & China


Study Period: 2019–2030


Current Clinical Practice and Treatment Algorithm

Country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs are being covered under this section of the study. Retrospective analysis and bench-marking of clinical study outcomes are being presented in terms of Pr-treatment & post-treatment clinical and demographic patient characteristics. Essentially the evolution of the current competitive landscape and its impact on the future treatment paradigm is being well covered under this section.

KOL Insights:-
KOLs across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)
- Data Inputs with sourcing
- Market Event and Product Event
- Country specific Forecast Model
- Market uptake and patient share uptake
- Attribute Analysis
- Analog Analysis
- Disease burden and pricing scenario
- Summary and Insights

NPV/ IRR Calculator-
Optimization of cash flow/ revenue flow concerning all fixed and variable investment throughout the product development process. Rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:
Competitive landscape includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review such as Orphan drug designation, Fast track, Priority review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation and Accelerated Approval are being tracked and supplemented with analyst commentary.

Clinical Trial Assessment-
Detailed clinical trial data analysis and key product positioning includes trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps in determining the potential of the key assets as well as their probable filing and launch date.

Unmet Medical Needs Overview-
This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other important unmet needs identified through our research, include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

TOC of the Report:-

1. AIH – Key Findings Summary
1.1. Clinical findings
1.1.1. Disease overview
1.1.2. Therapeutic practices
1.1.3. Future outlook
1.2. Commercial findings
1.2.1. AIH market scenario 2020
1.2.2. AIH market scenario 2025
1.2.3. AIH market scenario 2030
2. AIH Overview
2.1. Disease Introduction
2.2. Pathophysiology
2.3. Signs and Symptoms
2.4. Risk Factors
2.5. Etiology
2.6. Classification
2.7. Pathogenesis
2.8. Diagnosis
2.9. Complications
2.10. Treatment Algorithm
2.10.1. Treatment in US (guidelines)
2.10.2. Treatment in EU-5 (guidelines)
2.10.3. Treatment in Japan (guidelines)
2.10.4. Treatment in China (guidelines)
2.11. Treatment Goals for AIH
2.12. Referral Patterns
2.12.1. Referral Scenario in US
2.12.2. Referral Scenario in EU-5
2.12.3. Referral Scenario in Japan
2.12.4. Referral Scenario in China
2.13. AIH Prognosis
2.14.Healthcare burden
2.14.1. Healthcare burden in US
2.14.2. Healthcare burden in EU-5
2.14.3. Healthcare burden in Japan
2.14.4. Healthcare burden in China
2.15. Unmet Needs in AIH management
2.16. Market Opportunity for AIH
2.17. KOL Comments on current and upcoming/expected treatment practices in AIH
3. Epidemiology
3.1. Epidemiology Overview
3.2. Epidemiology by Geography
3.2.1. AIH Epidemiology in US (2019-2030)
3.2.1.1. Incidence of AIH
3.2.1.2. Diagnosed cases
3.2.1.3. Treatable Patient Pool
3.2.1.4. Epidemiology Trends
3.2.2. AIH Epidemiology in EU-5 (2019-2030)
3.2.2.1. Incidence of AIH
3.2.2.2. Diagnosed cases
3.2.2.3. Treatable Patient Pool
3.2.2.4. Epidemiology Trends
3.2.3. AIH Epidemiology in Japan (2019-2030)
3.2.3.1. Incidence of AIH
3.2.3.2. Diagnosed cases
3.2.3.3. Treatable Patient Pool
3.2.3.4. Epidemiology Trends
3.2.4. AIH Epidemiology in China (2019-2030)
3.2.4.1. Incidence of AIH
3.2.4.2. Diagnosed cases
3.2.4.3. Treatable Patient Pool
3.2.4.4. Epidemiology Trends
3.3. Epidemiology Trends (World-wide)
4. Market Outlook
4.1. US AIH Market Forecast 2019-2030
4.1.1. Market Progression (Futuristic)
4.1.2. Market Trends and Expectations
4.1.2.1. Worst case scenario
4.1.2.2. Base Case Scenario
4.1.2.3. Best Case Scenario
4.1.3. Drivers and Barriers
4.2. UK AIH Market Forecast 2019-2030
4.2.1. Market Progression (Futuristic)
4.2.2. Market Trends and Expectations
4.2.2.1. Worst case scenario
4.2.2.2. Base Case Scenario
4.2.2.3. Best Case Scenario
4.2.3. Drivers and Barriers
4.3. France AIH Market Forecast 2019-2030
4.3.1. Market Progression (Futuristic)
4.3.2. Market Trends and Expectations
4.3.2.1. Worst case scenario
4.3.2.2. Base Case Scenario
4.3.2.3. Best Case Scenario
4.3.3. Drivers and Barriers
4.4. Germany AIH Market Forecast 2019-2030
4.4.1. Market Progression (Futuristic)
4.4.2. Market Trends and Expectations
4.4.2.1. Worst case scenario
4.4.2.2. Base Case Scenario
4.4.2.3. Best Case Scenario
4.4.3. Drivers and Barriers
4.5. Italy AIH Market Forecast 2019-2030
4.5.1. Market Progression (Futuristic)
4.5.2. Market Trends and Expectations
4.5.2.1. Worst case scenario
4.5.2.2. Base Case Scenario
4.5.2.3. Best Case Scenario
4.5.3. Drivers and Barriers
4.6. Spain AIH Market Forecast 2019-2030
4.6.1. Market Progression (Futuristic)
4.6.2. Market Trends and Expectations
4.6.2.1. Worst case scenario
4.6.2.2. Base Case Scenario
4.6.2.3. Best Case Scenario
4.6.3. Drivers and Barriers
4.7. Japan AIH Market Forecast 2019-2030
4.7.1. Market Progression (Futuristic)
4.7.2. Market Trends and Expectations
4.7.2.1. Worst case scenario
4.7.2.2. Base Case Scenario
4.7.2.3. Best Case Scenario
4.7.3. Drivers and Barriers
4.8. China AIH Market Forecast 2019-2030
4.8.1. Market Progression (Futuristic)
4.8.2. Market Trends and Expectations
4.8.2.1. Worst case scenario
4.8.2.2. Base Case Scenario
4.8.2.3. Best Case Scenario
4.8.3. Drivers and Barriers
4.9. Key Expected Milestones (world-wide) Impacting the Market
5. Competitive Landscape
5.1. Pipeline Therapies Overview
5.1.1. Phase III Therapies
5.1.1.1. Current Status
5.1.1.2. Trial details, results
5.1.1.3. Approval Timeline
5.1.1.4. Likelihood of approval
5.1.1.5. Expected Product Positioning

5.1.2. Phase II and Phase I/II Therapies
5.1.2.1. Current Status
5.1.2.2. Trial details, results
5.1.2.3. Approval Timelines
5.1.3. List of active Pre-clinical Therapies
5.1.3.1. Status in AIH
5.1.3.2. Company positioning
5.1.3.2. All other pre-clinical therapies
5.1.4. List of Inactive/discontinued assets
5.1.4.1. Business impact of discontinuations on current pipeline
5.1.5. Potential winners from AIH Pipeline
5.1.5.1. Potential Blockbusters across the pipeline
6. Regulatory/Approval Scenario
6.1. Regulatory/Approval Framework in US
6.1.1. Policy Framework
6.1.2. Payer Expectations
6.2. Regulatory/Approval Framework in UK
6.2.1. Policy Framework
6.2.2. Payer Expectations
6.3. Regulatory/Approval Framework in France
6.3.1. Policy Framework
6.3.2. Payer Expectations
6.4. Regulatory/Approval Framework in Germany
6.4.1. Policy Framework
6.4.2. Payer Expectations
6.5. Regulatory/Approval Framework in Italy
6.5.1. Policy Framework
6.5.2. Payer Expectations
6.6. Regulatory/Approval Framework in Spain
6.6.1. Policy Framework
6.6.2. Payer Expectations
6.7. Regulatory/Approval Framework in Japan
6.7.1. Policy Framework
6.7.2. Payer Expectations
6.8. Regulatory/Approval Framework in China
6.8.1. Policy Framework
6.8.2. Payer Expectations
7. Clinical Trial Assessment – Current and Future Paradigm
7.1. Distribution of Primary Endpoints across trials
7.2. Distribution of Secondary Endpoints across trials
7.3. Evolution and acceptance of surrogate endpoints
7.4. Key Investigator initiated trials
7.5. Attrition analysis
7.5.1. Suspended/Discontinued Assets
7.5.2. Failed Trials, Reasons and Business Impact
7.5.3. Terminated Trials, Reasons and Business Impact
7.5.4. Withdrawn Trials, Reasons and Business Impact
7.6. Trial enrollment scenario and challenges
7.7. Clinical Trial Guidance (across geographies)
8. Thelansis Commentary
8.1. Key Unmet needs in AIH
8.2. Possible Best-case Clinical Trial Strategies
8.3. Possible Best Case Targeted Product Profile (TPP)
8.4. Possible Best-case Market positioning strategies
8.5. Possible Best-case Market Access Strategies
8.6. Possible Best-case LCM Strategies
8.7. Overall View on AIH Market in Dollar Value
9. Report Methodology
9.1. Secondary research
9.2. Primary research
9.3. Data collation
9.4. Insight Generation
10. About Thelansis
10.1. Our Capabilities
10.2. Our Services
10.3. Our Contacts
10.4. Disclaimer

Sales office
183-Asylum Street Hartford, CT-06103, USA
Contant:- USA +1 (267) 244-6955

Delivery office
Bengaluru- Embassy TechVillage, Kadabeesanahalli, Bengaluru-560013 India
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact India : +91(124) 404-1731

Email
clientsupport@thelansis.com
m.berg@thelansis.com

Thelansis known to provide therapy specific market insight reports which essentially covers Epidemiology and Market Forecast of 8 key markets (US, Germany, France, Spain, Italy, UK, Japan and China) in a advance excel based dynamic forecast model, enables client to understand the differnet scenario of the market over a period of 10 years.
Competitive landscape analysis covered in the Thelansis reports allows our clients to monitor competitor’s activity around targeted indications during a different phase of development (Early Phase, Phase I, II, and III) and post-approval phase.
Our services include epidemiology study, Market forecasting, clinical trial analytics, Pipeline assessment, enrollment projections, trialsite prioritization,
investigator profiling, and trial completion data projection, launch data estimation, and essentially the key product positioning.

Thelansis reports now coupled with KOL insights gathered from the the Primary market research (PMR) through in-house programmed web-based survey tool which helps our clients to fill the gap of real-time data, unmet needs, and critical strategic insights right from development to commercialization.

This release was published on openPR.